Advancing Bardet-Biedl Syndrome Treatment in China: Gene Therapy and Clinical Innovations at NCMC, Shanghai

Bardet-Biedl Syndrome (BBS) is a rare, multisystem genetic disorder characterized by symptoms such as retinal degeneration, obesity, polydactyly, kidney abnormalities, and cognitive impairments. With a global prevalence estimated between 1 in 70,000 to 1 in 160,000, BBS poses significant challenges due to its complexity and the lack of curative treatments. However, recent advancements in gene therapy and clinical research, particularly in China, are offering new hope for patients.

Gene therapy has emerged as a groundbreaking approach in addressing the root causes of BBS. Notably, Axovia Therapeutics is developing AXV101, an adeno-associated virus (AAV9)-based gene therapy targeting retinal dystrophy in patients with biallelic mutations in the BBS1 gene. This therapy aims to halt photoreceptor cell death and retinal degeneration, key contributors to vision loss in BBS patients. Preclinical studies have shown promising results, and the first-in-human clinical trial is scheduled to commence in mid-2025.

In parallel, research involving subretinal gene therapy in mice with BBS type 1 has demonstrated that AAV vector delivery can rescue BBSome formation and slightly improve retinal function, indicating potential applicability in human treatments.

The National Clinical Medical Center (NCMC) in Shanghai has positioned itself at the forefront of rare disease research in China. While details on BBS-focused trials at NCMC are limited, the center's commitment to advancing treatments for rare genetic disorders is evident through its extensive clinical research programs. NCMC's collaborations with international biotech firms and its involvement in multicenter studies underscore its role in bringing innovative therapies, including gene therapy, to patients in China.

Moreover, studies have highlighted the phenotypic diversity observed in Chinese BBS patients, which points to the importance of region-specific research and personalized treatment approaches.

Beyond gene therapy, GLP-1 receptor agonists, commonly used for type 2 diabetes and obesity, have shown potential in managing metabolic complications associated with BBS. Recent studies using BBS mouse models have demonstrated that GLP-1 therapies can significantly reduce food intake, promote weight loss, improve glucose tolerance, and normalize metabolic hormone levels. These findings suggest that GLP-1-based treatments could offer a valuable therapeutic option for BBS patients struggling with obesity and related metabolic issues.

The advancements in gene therapy and the exploration of GLP-1 therapies represent major victories in the quest to treat Bardet-Biedl Syndrome. China's active participation, through institutions like NCMC and collaborations with international biotech companies, highlights a global commitment to addressing this challenging disorder.

As clinical trials progress and research deepens, there is growing optimism that these innovative approaches will lead to effective treatments, improving the quality of life for BBS patients worldwide.